Fidelity led the $115m funding round in Wugen.

Fidelity, a private equity firm, led the $115m funding round in Wugen, a clinical-stage biotech focused on next-generation allogeneic CAR-T therapies, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling Capital Management, and other leading life sciences investors. “This financing comes at a decisive time for Wugen as we advance WU-CART-007 through our ongoing pivotal study with a clear path to a BLA filing in 2027,” Kumar Srinivasan, Wugen CEO.